Acer Therapeutics Compliant with All Nasdaq Listing Criteria
30 December 2022 - 12:30AM
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company
focused on the acquisition, development and commercialization of
therapies for serious rare and life-threatening diseases with
significant unmet medical needs, today announced that The Nasdaq
Stock Market LLC has formally notified Acer that the company has
regained compliance with the $35 million market value of listed
securities requirement, and otherwise satisfies all other criteria
necessary, for continued listing on The Nasdaq Capital Market.
Accordingly, the listing matter is now closed and the
previously-scheduled hearing before the Nasdaq Hearings Panel has
been cancelled.
About Acer TherapeuticsAcer is a pharmaceutical
company focused on the acquisition, development and
commercialization of therapies for serious rare and
life-threatening diseases with significant unmet medical needs. In
the U.S., OLPRUVA™ (sodium phenylbutyrate) is approved for the
treatment of urea cycle disorders (UCDs) involving deficiencies of
carbamylphosphate synthetase (CPS), ornithine transcarbamylase
(OTC), or argininosuccinic acid synthetase (AS). Acer is also
advancing a pipeline of investigational product candidates for rare
and life-threatening diseases, including: OLPRUVA™ (sodium
phenylbutyrate) for treatment of various other inborn errors of
metabolism, including Maple Syrup Urine Disease (MSUD); ACER-801
(osanetant) for treatment of induced Vasomotor Symptoms (iVMS) and
Post-traumatic Stress Disorder (PTSD); EDSIVO™ (celiprolol) for
treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients
with a confirmed type III collagen (COL3A1) mutation; and ACER-2820
(emetine), a host-directed therapy against a variety of viruses,
including cytomegalovirus, Zika, dengue, Ebola and COVID-19. For
more information, visit www.acertx.com.
Acer ContactsCorporate contact:Jim DeNikeAcer
Therapeutics Inc.jdenike@acertx.com+1-844-902-6100
Investor contact:Nick ColangeloGilmartin
Groupnick@gilmartinIR.com+1-332-895-3226
Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Apr 2023 to Apr 2024